VEGF‐C, VEGF‐D and VEGFR‐3 expression in peripheral neuroblastic tumours

Ramani, Pramila; Nash, Rachel; Radevsky, Lucy; Patel, Ameesh; Luckett, Michael; Rogers, Chris

doi:10.1111/j.1365-2559.2012.04307.x

Cited by 7 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIF2 expression, ECM alteration and VEGF expression in HR-NB also lead to new vascularization. These tumors show more aggressive features such as more immature states and more easily spreading metastasis [ 203 , 204 , 205 , 206 , 207 , 208 ]. Moreover, there is evidence that PI3K kinases promote VEGF expression via MYCN [ 209 , 210 ].…”

Section: Mycn Determines High-risk Neuroblastomamentioning

confidence: 99%

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment

Bartolucci

Montemurro

Raieli³

et al. 2022

Cancers

View full text Add to dashboard Cite

Among childhood cancers, neuroblastoma is the most diffuse solid tumor and the deadliest in children. While to date, the pathology has become progressively manageable with a significant increase in 5-year survival for its less aggressive form, high-risk neuroblastoma (HR-NB) remains a major issue with poor outcome and little survivability of patients. The staging system has also been improved to better fit patient needs and to administer therapies in a more focused manner in consideration of pathology features. New and improved therapies have been developed; nevertheless, low efficacy and high toxicity remain a staple feature of current high-risk neuroblastoma treatment. For this reason, more specific procedures are required, and new therapeutic targets are also needed for a precise medicine approach. In this scenario, MYCN is certainly one of the most interesting targets. Indeed, MYCN is one of the most relevant hallmarks of HR-NB, and many studies has been carried out in recent years to discover potent and specific inhibitors to block its activities and any related oncogenic function. N-Myc protein has been considered an undruggable target for a long time. Thus, many new indirect and direct approaches have been discovered and preclinically evaluated for the interaction with MYCN and its pathways; a few of the most promising approaches are nearing clinical application for the investigation in HR-NB.

show abstract

Section: Mycn Determines High-risk Neuroblastomamentioning

confidence: 99%

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment

Bartolucci

Montemurro

Raieli³

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Thus VEGF-A has been intensively investigated regarding its role in tumorigenesis and potential for cancer therapy. While VEGF-C and VEGF-D regulate the lymphangiogenesis [ 48 ]. VEGF appears to be a critical regulator of EC proliferation [ 49 ].…”

Section: Reviewmentioning

confidence: 99%

Heart regeneration, stem cells, and cytokines

Wang

Jia

et al. 2014

Regen Med Res

View full text Add to dashboard Cite

The human heart has limited regenerative capacity, which makes the reparative response after the cardiac infarction quite challenging. During the last decade, stem cells have become promising candidates for heart repair, owing to their potent differentiation capacity and paracrine cytokine secretion. Among the different types of stem cells, mesenchymal stem cells have high proliferative potential and secrete numerous cytokines, growth factors, and microRNAs. The paracrine cytokines play important roles in cardiac regeneration, neovascularization, anti-apoptosis, and anti-remodeling mechanisms, among others. This review summarizes the cytokines secreted by stem cells and their relative signaling pathways, which represent key mechanisms for heart regeneration and may serve as a promising future therapeutic strategy for myocardial infarction patients.

show abstract

“…Lymphangiogenesis in neuroblastoma is associated with upregulated VEGFC, VEGFD, and VEGFR3, which promotes lymph node metastasis and leads to poor prognosis. 147 Endogenous soluble VEGFR2 inhibits the activation of VEGFR3 by binding to VEGFC, thereby inhibiting LEC proliferation. In the context of advanced neuroblastoma, the downregulation of sVEGFR2 is correlated with the disease progression.…”

Section: Abnormal Lymphangiogenesis In Human Diseasesmentioning

confidence: 99%

Lymphatic vessel: Origin, heterogeneity, biological functions and therapeutic targets

Hu,

Zhao,

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Lymphatic vessels, comprising the secondary circulatory system in human body, play a multifaceted role in maintaining homeostasis among various tissues and organs. They are tasked with a serious of responsibilities, including the regulation of lymph absorption and transport, the orchestration of immune surveillance and responses. Lymphatic vessel development undergoes a series of sophisticated regulatory signaling pathways governing heterogeneous-origin cell populations stepwise to assemble into the highly specialized lymphatic vessel networks. Lymphangiogenesis, as defined by new lymphatic vessels sprouting from preexisting lymphatic vessels/embryonic veins, is the main developmental mechanism underlying the formation and expansion of lymphatic vessel networks in an embryo. However, abnormal lymphangiogenesis could be observed in many pathological conditions and has a close relationship with the development and progression of various diseases. Mechanistic studies have revealed a set of lymphangiogenic factors and cascades that may serve as the potential targets for regulating abnormal lymphangiogenesis, to further modulate the progression of diseases. Actually, an increasing number of clinical trials have demonstrated the promising interventions and showed the feasibility of currently available treatments for future clinical translation. Targeting lymphangiogenic promoters or inhibitors not only directly regulates abnormal lymphangiogenesis, but improves the efficacy of diverse treatments. In conclusion, we present a comprehensive overview of lymphatic vessel development and physiological functions, and describe the critical involvement of abnormal lymphangiogenesis in multiple diseases. Moreover, we summarize the targeting therapeutic values of abnormal lymphangiogenesis, providing novel perspectives for treatment strategy of multiple human diseases.

show abstract

VEGF‐C, VEGF‐D and VEGFR‐3 expression in peripheral neuroblastic tumours

Abstract: VEGF-D and VEGFR-3 up-regulation support tumour progression in NB and VEGFR-3c may provide a useful prognostic marker in NBs.

Cited by 7 publications

References 31 publications

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment

Heart regeneration, stem cells, and cytokines

Lymphatic vessel: Origin, heterogeneity, biological functions and therapeutic targets

Contact Info

Product

Resources

About